Telangana Chief Minister A. Revanth Reddy is scheduled to inaugurate the two-day event consisting of conferences, panel discussions and an exhibition, amid Telangana’s aspirations to consolidate and scale up in the Life Sciences industry.
| Photo Credit: File Photo
The stage is set for BioAsia 2026, the 23rd edition of the annual premier event focussed on Life Sciences, in Hyderabad from February 17.
Chief Minister A.Revanth Reddy is scheduled to inaugurate the two-day event consisting of conferences, panel discussions and an exhibition, amid Telangana’s aspirations to consolidate and scale up in the Life Sciences industry.
Indeed, all eyes will be on the State and its plans to sharpen focus and enhance the engagement with stakeholders in the global Life Sciences industry. Providing the backdrop will be the new, Next-Gen Life Sciences Policy 2026-30 Telangana government choose to unveil at the World Economic Forum (WEF) annual meeting in Davos last month. The document is expected to serve as a guiding framework as the State seeks to leapfrog from a scale-driven manufacturing approach to value-led, innovation-powered growth.
The government wants to position Telangana as a globally integrated Life Sciences hub across discovery, development and deployment as well as rank among the top five life sciences clusters worldwide by 2030. The new policy targets $25 billion in investments, creation of five lakh high-quality jobs and deeper integration into global life sciences value chains.
BioAsia will be held at a new expanded venue at HITEX to accommodate unprecedented demand from international delegates, investors, startups and global life sciences corporations. The move to a significantly larger space is not merely logistical — it signals BioAsia’s transition into a high-impact global platform capable of hosting multi-track executive sessions, expanded exhibitions, and curated investor-founder interactions under one roof, the organisers said in a release.
The event comes amid Hyderabad emerging as a preferred destination for the global capability centres of globally leading pharma and biotech firms, ramped up biologics and vaccine manufacturing capacity and new investments in bioprocess design, advanced therapies and AI-enabled healthcare. BioAsia 2026 organisers say the event is expected to further accelerate this momentum by catalysing strategic partnerships that extend beyond the event.
With ‘TechBio Unleashed: AI, Automation and the Biology Revolution’, BioAsia 2026 will spotlight the convergence of AI, automation and biological sciences. The event convenes high-impact global voices through plenaries, forward-looking panel dialogues, immersive exhibition engagement, expanded B2B partnering, and deeper cross-border collaboration, all centred on the TechBio inflection point, digital transformation, advanced biologics and next-generation manufacturing, the organisers said.
Published – February 16, 2026 10:27 pm IST
